• 1
    Hladik F, Hope TJ: HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6:2028.
  • 2
    UNAIDS\WHO. Report on global AIDS epidemic. Geneva, 2008.
  • 3
    Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M: Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118129.
  • 4
    Shattock RJ, Griffin GE, Gorodeski GI: In vitro models of mucosal HIV transmission. Nat Med 2000; 6:607608.
  • 5
    Hiller C, Bock U, Balser S, Haltner-Ukomadu E, Dahm M: Establishment and validation of an ex vivo human cervical tissue model for local delivery studies. Eur J Pharm Biopharm 2008; 68:390399.
  • 6
    Achkar JM, Fries BC: Candida infections of the genitourinary tract. Clin Microbiol Rev 2010; 23:253273.
  • 7
    Koelle DM, Corey L: Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008; 59:381395.
  • 8
    Norvell MK, Benrubi GI, Thompson RJ: Investigation of microtrauma after sexual intercourse. J Reprod Med 1984; 29:269271.
  • 9
    Sommers MS: Defining patterns of genital injury from sexual assault: a review. Trauma Violence Abuse 2007; 8:270280.
  • 10
    Jacobson DL, Peralta L, Graham NM, Zenilman J: Histologic development of cervical ectopy: relationship to reproductive hormones. Sex Transm Dis 2000; 27:252258.
  • 11
    Moscicki AB, Ma Y, Holland C, Vermund SH: Cervical ectopy in adolescent girls with and without human immunodeficiency virus infection. J Infect Dis 2001; 183:865870.
  • 12
    Shen R, Richter HE, Smith PD: Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am J Reprod Immunol 2010; doi: 10.1111/j.1600-0897.2010.00939.x. [Epub ahead of print].
  • 13
    Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217223.
  • 14
    Morrow G, Vachot L, Vagenas P, Robbiani M: Current concepts of HIV transmission. Curr Infect Dis Rep 2008; 10:133139.
  • 15
    Anderson DJ, Pudney J, Schust DJ: Caveats associated with the use of human cervical tissue for HIV and microbicide research. AIDS 2010; 24:14.
  • 16
    Carrel A: On the permanent life of tissues outside of the organism. J Exp Med 1912; 15:516528.
  • 17
    Grivel JC, Margolis L: Use of human tissue explants to study human infectious agents. Nat Protoc 2009; 4:256269.
  • 18
    Leighton J: A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. J Natl Cancer Inst 1951; 12:545561.
  • 19
    Leighton J: A method for the comparison of the fate of intravascular tumor-cell emboli in vivo and in organ culture. Natl Cancer Inst Monogr 1963; 11:157195.
  • 20
    Hoffman RM: Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 1991; 3:8692.
  • 21
    Glushakova S, Baibakov B, Margolis LB, Zimmerberg J: Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med 1995; 1:13201322.
  • 22
    Grivel JC, Malkevitch N, Margolis L: Human immunodeficiency virus type 1 induces apoptosis in CD4(+) but not in CD8(+) T cells in ex vivo-infected human lymphoid tissue. J Virol 2000; 74:80778084.
  • 23
    Grivel JC, Margolis LB: CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nat Med 1999; 5:344346.
  • 24
    Grivel JC, Penn ML, Eckstein DA, Schramm B, Speck RF, Abbey NW, Herndier B, Margolis L, Goldsmith MA: Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue. J Virol 2000; 74:53475351.
  • 25
    Lisco A, Grivel JC, Biancotto A, Vanpouille C, Origgi F, Malnati MS, Schols D, Lusso P, Margolis LB: Viral interactions in human lymphoid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 2007; 81:708717.
  • 26
    Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, Margolis LB: Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med 1998; 4:346349.
  • 27
    Grivel JC, Santoro F, Chen S, Faga G, Malnati MS, Ito Y, Margolis L, Lusso P: Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. J Virol 2003; 77:82808289.
  • 28
    Grivel JC, Ito Y, Faga G, Santoro F, Shaheen F, Malnati MS, Fitzgerald W, Lusso P, Margolis L: Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med 2001; 7:12321235.
  • 29
    Biancotto A, Iglehart SJ, Lisco A, Vanpouille C, Grivel JC, Lurain NS, Reichelderfer PS, Margolis LB: Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo. AIDS Res Hum Retroviruses 2008; 24:453462.
  • 30
    Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B, Elliott J, Fromentin E, Shattock R, Anton P, Gorelick R, Balzarini J, McGuigan C, Derudas M, Gotte M, Schinazi RF, Margolis L: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4:260270.
  • 31
    Vanpouille C, Biancotto A, Lisco A, Brichacek B: Interactions between human immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex vivo. J Virol 2007; 81:1245812464.
  • 32
    Condack C, Grivel JC, Devaux P, Margolis L, Cattaneo R: Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. J Infect Dis 2007; 196:541549.
  • 33
    Grivel JC, Garcia M, Moss W, Margolis L: Measles virus inhibits HIV-1 replication in human lymphoid tisue ex vivo. J Infect Dis 2005; 192:7178.
  • 34
    Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM: Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009; 5:e1000321.
  • 35
    Duray PH, Yin SR, Ito Y, Bezrukov L, Cox C, Cho MS, Fitzgerald W, Dorward D, Zimmerberg J, Margolis L: Invasion of human tissue ex vivo by Borrelia burgdorferi. J Infect Dis 2005; 191:17471754.
  • 36
    Sassi A, Brichacek B, Hieny S, Yarovinsky F, Golding H, Grivel JC, Sher A, Margolis L: Toxoplasma gondii inhibits R5 HIV-1 replication in human lymphoid tissues ex vivo. Microbes Infect 2009; 11:11061113.
  • 37
    Cummins Jr JE, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS: Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007; 51:17701779.
  • 38
    Palacio J, Souberbielle BE, Shattock RJ, Robinson G, Manyonda I, Griffin GE: In vitro HIV1 infection of human cervical tissue. Res Virol 1994; 145:155161.
  • 39
    Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, Lisco A: HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010; 3:280290.
  • 40
    Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P: Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 2000; 6:475479.
  • 41
    Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins Jr JE, Fink A, Gilmore GT, Staley C, Ward A, Ali O, Binderow S, Cohen S, Grohskopf LA, Paxton L, Hart CE, Dezzutti CS: A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 2005; 192:15451556.
  • 42
    Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ: Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:12371245.
  • 43
    Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P: HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS 2007; 21:12631272.
  • 44
    Fink CG, Thomas GH, Allen JM, Jordan JA: Metaplasia in endocervical tissue maintained in organ culture – an experimental model. J Obstet Gynaecol Br Commonw 1973; 80:169175.
  • 45
    Birch J, Fink CG, Skinner GR, Thomas GH, Jordan JA: Replication of type 2 herpes simplex virus in human endocervical tissue in organ culture. Br J Exp Pathol 1976; 57:460471.
  • 46
    O’Brien ME, Souberbielle BE, Cowan ME, Allen CA, Luesley DM, Mould JJ, Blackledge GR, Skinner GR: Glycoprotein patterns in normal and malignant cervical tissue. Cancer Lett 1991; 58:247254.
  • 47
    Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ: Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:55775586.
  • 48
    Gupta P, Collins K, Patterson B, Naus G, Landers D: Reply to ‘In vitro models of mucosal HIV transmission’. Nat Med 2000; 6:607608.
  • 49
    Gupta P, Collins KB, Ratner D, Watkins S, Naus GJ, Landers DV, Patterson BK: Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol 2002; 76:98689876.
  • 50
    Maher D, Wu X, Schacker T, Horbul J, Southern P: HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A 2005; 102:1150411509.
  • 51
    Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257270.
  • 52
    Gupta P, Ratner D, Patterson BK, Kulka K, Rohan LC, Parniak MA, Isaacs CE, Hillier S: Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. AIDS Res Hum Retroviruses 2006; 22:419424.
  • 53
    Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC: Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 2009; 26:502511.
  • 54
    Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS: In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 2010; 5:e9310.
  • 55
    Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ: Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 2009; 90:234243.
  • 56
    Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R: Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53:487495.
  • 57
    Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R: The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005; 79:1117911186.
  • 58
    Fletcher PS, Harman SJ, Boothe AR, Doncel GF, Shattock RJ: Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology 2008; 5:3.
  • 59
    Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ: Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199:10651075.
  • 60
    Hu Q, Younson J, Griffin GE, Kelly C, Shattock RJ: Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway. J Infect Dis 2006; 194:15471556.
  • 61
    Rodriguez MA, Ding M, Ratner D, Chen Y, Tripathy SP, Kulkarni SS, Chatterjee R, Tarwater PM, Gupta P: High replication fitness and transmission efficiency of HIV-1 subtype C from India: implications for subtype C predominance. Virology 2009; 385:416424.
  • 62
    Lisco A, Vanpouille C, Margolis L: War and peace between microbes: HIV-1 interactions with coinfecting viruses. Cell Host Microbe 2009; 6:403408.
  • 63
    Lisco A, Vanpouille C, Margolis L: Coinfecting viruses as determinants of HIV disease. Curr HIV/AIDS Rep 2009; 6:512.
  • 64
    Pease JE, Murphy PM: Microbial corruption of the chemokine system: an expanding paradigm. Semin Immunol 1998; 10:169178.
  • 65
    Alfano M, Crotti A, Vicenzi E, Poli G: New players in cytokine control of HIV infection. Curr HIV/AIDS Rep 2008; 5:2732.
  • 66
    Modjarrad K, Vermund SH: Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 2010; 10:455463.
  • 67
    Israel N, Hazan U, Alcami J, Munier A, Arenzana-Seisdedos F, Bachelerie F, Israel A, Virelizier JL: Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. J Immunol 1989; 143:39563960.
  • 68
    de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TB: TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 2008; 118:34403452.
  • 69
    Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE, Luque AE, Coombs R: Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses 2010; doi: 10.1089/aid.2010.0129. [Epub ahead of print].
  • 70
    Narimatsu R, Wolday D, Patterson BK: IL-8 increases transmission of HIV type 1 in cervical explant tissue. AIDS Res Hum Retroviruses 2005; 21:228233.
  • 71
    Rollenhagen C, Asin SN: IL-8 decreases HIV-1 transcription in peripheral blood lymphocytes and ectocervical tissue explants. J Acquir Immune Defic Syndr 2010; 54:463469.
  • 72
    Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, Huraux JM, Mayaud P, Nagot N: Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490497.
  • 73
    Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C: Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824833.
  • 74
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:11681174.
  • 75
    Lurain NS, Robert ES, Xu J, Camarca M, Landay A, Kovacs AA, Reichelderfer PS: HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis 2004; 190:619623.
  • 76
    Sheth PM, Danesh A, Sheung A, Rebbapragada A, Shahabi K, Kovacs C, Halpenny R, Tilley D, Mazzulli T, MacDonald K, Kelvin D, Kaul R: Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation. J Infect Dis 2006; 193:4548.
  • 77
    Fox-Canale AM, Hope TJ, Martinson J, Lurain JR, Rademaker AW, Bremer JW, Landay A, Spear GT, Lurain NS: Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology 2007; 369:5568.
  • 78
    Wira CR, Ghosh M, Smith JM, Shen L, Connor RI, Sundstrom P, Frechette GM, Hill ET, Fahey JV: Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol 2010; doi: 10.1038/mi.2010.72 [Epub ahead of print].
  • 79
    Castelletti E, Lo Caputo S, Kuhn L, Borelli M, Gajardo J, Sinkala M, Trabattoni D, Kankasa C, Lauri E, Clivio A, Piacentini L, Bray DH, Aldrovandi GM, Thea DM, Veas F, Nebuloni M, Mazzotta F, Clerici M: The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS ONE 2007; 2:e969.
  • 80
    Kim RH, Yochim JM, Kang MK, Shin KH, Christensen R, Park NH: HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol 2008; 33:777782.
  • 81
    Diaz JJ, Dodon MD, Schaerer-Uthurralt N, Simonin D, Kindbeiter K, Gazzolo L, Madjar JJ: Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996; 379:273277.
  • 82
    Margolis DM, Rabson AB, Straus SE, Ostrove JM: Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992; 186:788791.
  • 83
    Mosca JD, Bednarik DP, Raj NB, Rosen CA, Sodroski JG, Haseltine WA, Pitha PM: Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987; 325:6770.
  • 84
    Asin SN, Eszterhas SK, Rollenhagen C, Heimberg AM, Howell AL: HIV type 1 infection in women: increased transcription of HIV type 1 in ectocervical tissue explants. J Infect Dis 2009; 200:965972.
  • 85
    Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, Stanley S, Fauci AS: Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990; 172:151158.
  • 86
    Cates Jr W: After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet 2010; 376:495496.
  • 87
    Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463472.
  • 88
    Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC, Shattock RJ: Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol 2008; 82:65766584.
  • 89
    Klasse PJ, Shattock R, Moore JP: Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455471.
  • 90
    Keele BF, Derdeyn CA: Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS 2009; 4:352357.
  • 91
    Keele BF: Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS 2010; 5:327334.
  • 92
    Margolis L, Shattock R: Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol 2006; 4:312317.
  • 93
    Galvin SR, Cohen MS: The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:3342.
  • 94
    Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K: Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682690.